This study looked at ways to improve the quality of life of people with mesothelioma of the chest (pleural mesothelioma). This study was open for people to join between April 2014 and October 2016.
HDAC I/IIb selective inhibitor purinostat mesylate in relapsed and refractory diffuse large B-cell lymphoma: A single agent phase IIa trial. This is an ASCO Meeting Abstract from the 2024 ASCO Annual ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. In a recent update, NovoCure Ltd.
A cancer diagnosis is never good news – and a diagnosis of malignant mesothelioma may be the worst news of all. However, an innovative therapy, developed by Professor Peter Szlosarek and his team in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback